- Home
- KRUS vs SBFM Comparison
KRUS vs SBFM Comparison
Compare KRUS & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRUS
- SBFM
- Stock Information
- Founded
- KRUS 2008
- SBFM 2006
- Country
- KRUS United States
- SBFM United States
- Employees
- KRUS N/A
- SBFM N/A
- Industry
- KRUS Restaurants
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- KRUS Consumer Discretionary
- SBFM Health Care
- Exchange
- KRUS Nasdaq
- SBFM Nasdaq
- Market Cap
- KRUS N/A
- SBFM 4.9M
- IPO Year
- KRUS 2019
- SBFM N/A
- Fundamental
- Price
- KRUS $58.50
- SBFM $1.25
- Analyst Decision
- KRUS Buy
- SBFM Strong Buy
- Analyst Count
- KRUS 9
- SBFM 1
- Target Price
- KRUS $74.67
- SBFM $15.00
- AVG Volume (30 Days)
- KRUS 414.4K
- SBFM 3.7M
- Earning Date
- KRUS 04-08-2025
- SBFM 05-19-2025
- Dividend Yield
- KRUS N/A
- SBFM N/A
- EPS Growth
- KRUS N/A
- SBFM N/A
- EPS
- KRUS N/A
- SBFM N/A
- Revenue
- KRUS $258,444,000.00
- SBFM $34,874,283.00
- Revenue This Year
- KRUS $19.94
- SBFM $192.48
- Revenue Next Year
- KRUS $21.13
- SBFM N/A
- P/E Ratio
- KRUS N/A
- SBFM N/A
- Revenue Growth
- KRUS 21.37
- SBFM 44.75
- 52 Week Low
- KRUS $40.03
- SBFM $1.19
- 52 Week High
- KRUS $121.99
- SBFM $91.40
- Technical
- Relative Strength Index (RSI)
- KRUS 55.95
- SBFM 27.96
- Support Level
- KRUS $45.71
- SBFM $1.36
- Resistance Level
- KRUS $57.84
- SBFM $1.65
- Average True Range (ATR)
- KRUS 5.29
- SBFM 0.31
- MACD
- KRUS 1.59
- SBFM -0.04
- Stochastic Oscillator
- KRUS 97.72
- SBFM 2.97
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.